| Previous Close | 2.50 |
| Open | 2.50 |
| Bid | 2.45 x 1400 |
| Ask | 2.55 x 600 |
| Day's Range | 2.50 - 2.55 |
| 52 Week Range | 2.10 - 4.45 |
| Volume | 13,003 |
| Avg. Volume | 31,177 |
| Market Cap | 59.6M |
| Beta | N/A |
| PE Ratio (TTM) | -1.07 |
| EPS (TTM) | -2.33 |
| Earnings Date | Nov 13, 2017 - Nov 17, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 76.00 |
- Associated Press•8 days ago
Atyr Pharma reports 2Q loss
On a per-share basis, the San Diego-based company said it had a loss of 51 cents. In the final minutes of trading on Monday, the company's shares hit $3.25. A year ago, they were trading at $3.42. _____ ...
- GlobeNewswire•9 days ago
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
–Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies–– iMod.Fc Program for Interstitial Lung Disease on Track to Commence Phase 1 Clinical Trial–– Project ...
- GlobeNewswire•13 days ago
aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results
SAN DIEGO, Aug. 10, 2017-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, will report its financial ...
